OncoMatch/Clinical Trials/NCT05958121
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
Is NCT05958121 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including IMA402 (Phase Ia) and IMA402 (Phase Ib) for refractory cancer.
Treatment: IMA402 (Phase Ia) · IMA402 (Phase Ib) · IMA402 (Phase II) — The goal of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumors. Primary objectives: * To determine the maximum tolerated dose and/or recommended dose for extension for IMA402 (Phase I) * To characterize the safety and tolerability of IMA402 (Phase I/II) * To evaluate anti-tumor activity of IMA402 (Phase II) Secondary objectives: * To evaluate the initial anti-tumor activity of IMA402 (Phase I) * To evaluate anti-tumor activity of IMA402 (Phase II) * To describe the PK of IMA402 (Phase I/II)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available indicated standard-of-care treatments
Patients must have received or not be eligible for all available indicated standard-of-care treatments
Lab requirements
Blood counts
adequate baseline hematologic function
Kidney function
adequate baseline renal function
Liver function
adequate baseline hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05958121 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received all available indicated standard-of-care treatments.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify